We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+43.17%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.56B
AUM Growth
+$116M
Cap. Flow
-$176M
Cap. Flow %
-4.93%
Top 10 Hldgs %
45.81%
Holding
127
New
13
Increased
20
Reduced
25
Closed
31

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$79.7M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$45.9M
3
PCVX icon
Vaxcyte
PCVX
+$45.9M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$39.2M
5
ACRV icon
Acrivon Therapeutics
ACRV
+$38.2M

Top Sells

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$158M
2
RLMD icon
Relmada Therapeutics
RLMD
+$88.2M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$43.3M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$38.4M
5
EW icon
Edwards Lifesciences
EW
+$27.3M

Sector Composition

Rank Sector Weight
1 Healthcare 97.34%
2 Financials 0.08%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VERU icon
26
Veru
VERU
$47.1M
$41.5M 1.17%
785,801
+396,501
+102% +$32.6M
ALBO
27
DELISTED
Albireo Pharma Inc
ALBO
$38M 1.07%
1,757,160
-602,979
-26% -$12.7M
COGT icon
28
Cogent Biosciences
COGT
$6.37B
$37.1M 1.04%
3,207,441
– –
VRDN icon
29
Viridian Therapeutics
VRDN
$2.73B
$35.7M 1%
1,220,575
– –
RAPT
30
DELISTED
RAPT Therapeutics
RAPT
$35.6M 1%
224,869
+10,727
+5% +$1.72M
ZYME icon
31
Zymeworks
ZYME
$2.12B
$35.5M 1%
4,511,275
+111,176
+3% +$781K
ACRV icon
32
Acrivon Therapeutics
ACRV
$90.4M
$34.7M 0.97%
+3,007,858
New +$38.2M
ESTA icon
33
Establishment Labs
ESTA
$2.16B
$32.7M 0.92%
497,857
-80,396
-14% -$4.86M
ATXS
34
DELISTED
Astria Therapeutics
ATXS
$32.6M 0.92%
2,189,462
+908,265
+71% +$9.37M
CINC
35
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$31.7M 0.89%
2,576,325
-730,324
-22% -$17.4M
IMTX icon
36
Immatics
IMTX
$1.25B
$30.4M 0.85%
3,491,500
+991,500
+40% +$10.3M
RLAY icon
37
Relay Therapeutics
RLAY
$4.27B
$29M 0.82%
1,943,097
– –
LYRA
38
DELISTED
LYRA THERAPEUTICS INC
LYRA
$28.7M 0.81%
182,935
– –
OM icon
39
Outset Medical
OM
$80.1M
$28.1M 0.79%
72,628
-5,281
-7% -$1.49M
HRMY icon
40
Harmony Biosciences
HRMY
$2.3B
$22.7M 0.64%
411,804
– –
RCKT icon
41
Rocket Pharmaceuticals
RCKT
$397M
$21.1M 0.59%
1,078,204
+578,204
+116% +$10.6M
VBIV
42
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$20.4M 0.57%
1,744,500
– –
RAIN
43
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$19.9M 0.56%
2,483,619
– –
AKRO
44
DELISTED
Akero Therapeutics
AKRO
$19.2M 0.54%
350,525
-79,475
-18% -$3.41M
TARS icon
45
Tarsus Pharmaceuticals
TARS
$3.1B
$19M 0.53%
1,296,416
– –
SLDB icon
46
Solid Biosciences
SLDB
$1.04B
$18.8M 0.53%
3,495,933
+2,601,763
+291% +$17.1M
NAUT icon
47
Nautilus Biotechnolgy
NAUT
$119M
$16.4M 0.46%
9,111,151
– –
ROIV icon
48
Roivant Sciences
ROIV
$26.4B
$15.8M 0.44%
+1,981,570
New +$11M
LONA
49
LeonaBio Inc
LONA
$73.3M
$15.2M 0.43%
479,728
– –
PRTA icon
50
Prothena Corp
PRTA
$474M
$14.3M 0.4%
237,646
+7,646
+3% +$448K
1
2
3 4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q4 2022 Portfolio in Review

As of Q4 2022, Perceptive Advisors held 127 positions worth $3.56B, up 3.4% from $3.45B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Perceptive Advisors withdrew a net $176M in Q4 2022, closing 31 positions and reducing 25 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $158M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Financials and Consumer Staples.

Against the trend, Perceptive Advisors opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares worth $109M.

  • Perceptive Advisors's largest Q4 2022 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 960,000 shares worth $109M.
  • Perceptive Advisors added most to Sarepta Therapeutics in Q4 2022, an estimated $45.9M increase.
  • Perceptive Advisors's biggest Q4 2022 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $38.4M.
  • Perceptive Advisors fully exited Global Blood Therapeutics, Inc. in Q4 2022, selling an estimated $158M.
  • Perceptive Advisors's ten largest holdings make up 46% of its $3.56B portfolio in Q4 2022.
  • Perceptive Advisors opened 13 new positions and closed 31 in Q4 2022.
  • Perceptive Advisors's portfolio value rose 3.4% quarter-over-quarter to $3.56B.

Based on Perceptive Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.